Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Amneal Pharmaceuticals, Inc.

< Previous 1 2 3 4 Next >
Amneal to Report Second Quarter 2022 Results on August 5, 2022
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Releases 2021 Corporate Responsibility Report Highlighting Continued ESG Impact and Integration
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Launches LYVISPAH® (baclofen) for Spasticity Related to Multiple Sclerosis and Other Spinal Cord Disorders
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk)
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Participate at the 2022 Jefferies Healthcare Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Participate at Upcoming Investor Conferences in May
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Reports First Quarter 2022 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Report First Quarter 2022 Results on May 4, 2022
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Present Results From the Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 at the 2022 American Academy of Neurology Annual Meeting
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Awarded Sub-License to Manufacture and Commercialize Generic Version of Co-Packaged Nirmatrelvir and Ritonavir in 95 Low- and Middle-Income Countries
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Expands Injectables Portfolio with 4 New Products
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Report Fourth Quarter and Full Year 2021 Results on March 2, 2022
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Acquires Saol Therapeutics’ Baclofen Franchise
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Virtually Participate at the 40th Annual J.P. Morgan Healthcare Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Receives Approval for Difluprednate Ophthalmic Emulsion
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Virtually Participate at Upcoming Investor Conferences
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Reports Third Quarter 2021 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Releases Inaugural Corporate Responsibility Report Highlighting Our Impact as a Socially Responsible Company
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Launches Generic Dexamethasone Following ANDA Approval by FDA
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Report Third Quarter 2021 Results on November 3, 2021
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Virtually Participate at Morgan Stanley 19th Annual Global Healthcare Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Announces Positive Topline Results from Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Announces Virtual Event to Discuss Initial Data from Pivotal Phase 3 Study of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Reports Second Quarter 2021 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Receives Approval for Generic TobraDex®
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Report Second Quarter 2021 Results on August 9, 2021
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Announces U.S. FDA Filing Acceptance of Biologics License Application (BLA) for Bevacizumab
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal Announces Dihydroergotamine (DHE) Autoinjector NDA for Migraines and Cluster Headaches
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
Amneal to Virtually Participate at Upcoming Investor Conferences
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Tickers AMRX
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.